Genmab — November 2024
-
Genmab stiller med 20 indlæg ved ASH-konference https://proinvestor.com/investornyt/1238337/genmab-stiller-med-20-indlaeg-ved-ash-konference
-
Genmab to Highlight Epcoritamabs Promising Role in Non-Hodgkin Lymphoma Treatment at ASH Annual Meeting https://csimarket.com/news/genmab-to-highlight-epcoritamab-s-promising-role-in-non-hodgkin-lymphoma-treatment-at-ash-annual-meeting2024-11-06026109
-
Minhua Chu
@chuminhua432
?? $ABBV AbbVie's BLA for epcoritamab (Epkinly) has been accepted by China's NMPA. https://x.com/chuminhua432/status/1854089849185460624 -
same in chinese https://www.forbeschina.com/innovation/innovation/69032
-
small new (sub)trial - Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
https://clinicaltrials.gov/study/NCT06676033 -
https://www.fiercepharma.com/pharma/drugs-unmet-needs-and-those-experienced-companies-have-best-chance-successful-launches Genmab and AbbVie’s debut of Epkinly for patients with diffuse large B-cell lymphoma has also exceeded expectations in its battle with
Columvi. -
“The company’s go-to-market strategy focused on leveraging the first-mover advantage with a focus on key accounts and customers, utilizing field medical, sales and market access teams across both Genmab and AbbVie,” Trinity wrote. “Genmab and AbbVie’s combined experience in hematology-oncology certainly helped navigate the early diagnosis, treatment and reimbursement realities inherent in complex new therapies of this type.”
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind